FARMERS & MERCHANTS TRUST Co OF LONG BEACH Purchases 2,479 Shares of Pfizer Inc. (NYSE:PFE)

FARMERS & MERCHANTS TRUST Co OF LONG BEACH boosted its position in Pfizer Inc. (NYSE:PFE) by 5.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 52,434 shares of the biopharmaceutical company’s stock after acquiring an additional 2,479 shares during the quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH’s holdings in Pfizer were worth $2,255,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in PFE. OLD Mission Capital LLC bought a new stake in shares of Pfizer during the third quarter worth $291,000. Ironwood Wealth Management LLC. grew its stake in shares of Pfizer by 1.6% during the first quarter. Ironwood Wealth Management LLC. now owns 35,385 shares of the biopharmaceutical company’s stock worth $1,282,000 after buying an additional 550 shares during the last quarter. Hoylecohen LLC grew its stake in shares of Pfizer by 81.6% during the first quarter. Hoylecohen LLC now owns 27,614 shares of the biopharmaceutical company’s stock worth $1,000,000 after buying an additional 12,404 shares during the last quarter. Childress Capital Advisors LLC grew its stake in shares of Pfizer by 75.9% during the first quarter. Childress Capital Advisors LLC now owns 13,256 shares of the biopharmaceutical company’s stock worth $480,000 after buying an additional 5,719 shares during the last quarter. Finally, Regency Capital Management Inc. DE bought a new stake in shares of Pfizer during the first quarter worth $71,000. 64.99% of the stock is currently owned by institutional investors and hedge funds.

In other news, insider John D. Young sold 150,000 shares of the company’s stock in a transaction dated Thursday, November 11th. The shares were sold at an average price of $50.06, for a total transaction of $7,509,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 0.05% of the stock is currently owned by corporate insiders.

A number of research firms have weighed in on PFE. Royal Bank of Canada set a $44.00 target price on shares of Pfizer in a research note on Thursday, July 29th. Mizuho reissued a “hold” rating and issued a $43.00 price objective on shares of Pfizer in a research note on Sunday, October 3rd. Truist Securities boosted their price objective on shares of Pfizer from $43.00 to $58.00 and gave the stock a “buy” rating in a research note on Wednesday. Cantor Fitzgerald reissued a “buy” rating and issued a $60.00 price objective on shares of Pfizer in a research note on Friday, November 5th. Finally, Independent Research raised shares of Pfizer to a “buy” rating and set a $53.00 price objective on the stock in a research note on Thursday, November 11th. Eight analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, Pfizer presently has an average rating of “Hold” and a consensus price target of $49.00.

PFE stock traded down $0.19 during midday trading on Thursday, hitting $50.89. The stock had a trading volume of 18,556,753 shares, compared to its average volume of 30,943,912. The firm has a market cap of $285.64 billion, a P/E ratio of 15.15, a price-to-earnings-growth ratio of 1.16 and a beta of 0.72. The company has a current ratio of 1.37, a quick ratio of 1.12 and a debt-to-equity ratio of 0.50. Pfizer Inc. has a 1-year low of $33.36 and a 1-year high of $52.83. The business has a fifty day moving average price of $45.01 and a two-hundred day moving average price of $43.27.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, November 2nd. The biopharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.08 by $0.26. The business had revenue of $24.09 billion for the quarter, compared to analyst estimates of $22.82 billion. Pfizer had a net margin of 27.66% and a return on equity of 31.66%. Pfizer’s revenue for the quarter was up 134.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.72 earnings per share. On average, equities analysts anticipate that Pfizer Inc. will post 4.2 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 6th. Stockholders of record on Friday, November 5th will be issued a dividend of $0.39 per share. The ex-dividend date of this dividend is Thursday, November 4th. This represents a $1.56 annualized dividend and a dividend yield of 3.07%. Pfizer’s dividend payout ratio is currently 46.43%.

Pfizer Company Profile

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

Featured Story: How to Invest in a Bull Market

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.